MOONLAKE IMMUNOTHERAPEUTICS Operating Cash Flow
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Operating Cash Flow of -$121.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$55.56M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$66.29M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$58.79M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$44.54M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for fiscal 2025 was -$196.01M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for fiscal 2024 was -$116.59M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for fiscal 2023 was -$42.78M.
- MOONLAKE IMMUNOTHERAPEUTICS net cash provided by (used in) operating activities for fiscal 2022 was -$55.89M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 10 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$55.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$121.84M 10-Q · filed 2026-08-10 | -$180.64M derived: sum of 3 quarters · filed 2026-08-10 | -$225.18M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2026-03-31 | -$66.29M 10-Q · filed 2026-05-11 | -$125.08M derived: sum of 2 quarters · filed 2026-05-11 | -$169.62M derived: sum of 3 quarters · filed 2026-05-11 | -$224.15M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2025-12-31 | -$58.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$103.34M derived: sum of 2 quarters · filed 2026-02-25 | -$157.87M derived: sum of 3 quarters · filed 2026-08-10 | -$196.01M 10-K · filed 2026-02-25 | ||||||
| 2025-09-30 | -$44.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$99.07M derived: sum of 2 quarters · filed 2026-08-10 | -$137.21M 10-Q · filed 2025-11-05 | -$185.69M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2025-06-30 | -$54.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$92.67M 10-Q · filed 2026-08-10 | -$141.14M derived: sum of 3 quarters · filed 2026-08-10 | -$166.42M derived: sum of 4 quarters · filed 2026-08-10 | ||||||
| 2025-03-31 | -$38.14M 10-Q · filed 2026-05-11 | -$86.61M derived: sum of 2 quarters · filed 2026-05-11 | -$111.89M derived: sum of 3 quarters · filed 2026-05-11 | -$139.78M derived: sum of 4 quarters · filed 2026-05-11 | ||||||
| 2024-12-31 | -$48.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$73.75M derived: sum of 2 quarters · filed 2026-02-25 | -$101.64M derived: sum of 3 quarters · filed 2026-02-25 | -$116.59M 10-K · filed 2026-02-25 | -$116.59M 10-K · filed 2025-02-26 | |||||
| 2024-09-30 | -$25.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$53.17M derived: sum of 2 quarters · filed 2025-11-05 | -$68.11M 10-Q · filed 2025-11-05 | -$68.11M 10-Q · filed 2024-11-07 | -$80.46M derived: sum of 4 quarters · filed 2026-02-25 | |||||
| 2024-06-30 | -$27.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$42.84M 10-Q · filed 2025-08-05 | -$42.84M 10-Q · filed 2024-08-07 | -$55.18M derived: sum of 3 quarters · filed 2026-02-25 | -$64.43M derived: sum of 4 quarters · filed 2026-02-25 | |||||
| 2024-03-31 | -$14.95M 10-Q · filed 2025-05-12 | -$14.95M 10-Q · filed 2024-05-07 | -$27.29M derived: sum of 2 quarters · filed 2026-02-25 | -$36.54M derived: sum of 3 quarters · filed 2026-02-25 | -$48.70M derived: sum of 4 quarters · filed 2026-02-25 | |||||
| 2023-12-31 | -$12.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$21.59M derived: sum of 2 quarters · filed 2026-02-25 | -$33.75M derived: sum of 3 quarters · filed 2026-02-25 | -$42.78M 10-K · filed 2026-02-25 | -$42.78M 10-K · filed 2024-02-29 | |||||
| 2023-09-30 | -$9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$21.41M derived: sum of 2 quarters · filed 2024-11-07 | -$30.43M 10-Q · filed 2024-11-07 | -$42.03M derived: sum of 4 quarters · filed 2025-02-26 | ||||||
| 2023-06-30 | -$12.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$21.18M 10-Q · filed 2024-08-07 | -$32.78M derived: sum of 3 quarters · filed 2025-02-26 | -$42.13M derived: sum of 4 quarters · filed 2025-02-26 | ||||||
| 2023-03-31 | -$9.02M 10-Q · filed 2024-05-07 | -$20.62M derived: sum of 2 quarters · filed 2025-02-26 | -$29.97M derived: sum of 3 quarters · filed 2025-02-26 | -$50.73M derived: sum of 4 quarters · filed 2025-02-26 | ||||||
| 2022-12-31 | -$11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$20.95M derived: sum of 2 quarters · filed 2025-02-26 | -$41.71M derived: sum of 3 quarters · filed 2025-02-26 | -$55.89M 10-K · filed 2025-02-26 | ||||||
| 2022-09-30 | -$9.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$30.11M derived: sum of 2 quarters · filed 2023-11-14 | -$44.30M 10-Q · filed 2023-11-14 | -$17.19M derived: sum of 4 quarters · filed 2023-11-14 | ||||||
| 2022-06-30 | -$20.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$34.95M 10-Q · filed 2023-08-10 | -$7.83M derived: sum of 3 quarters · filed 2023-08-10 | -$9.85M derived: sum of 4 quarters · filed 2023-08-10 | ||||||
| 2022-03-31 | -$14.19M 10-Q · filed 2023-05-11 | -$793.45K 10-Q · filed 2022-05-16 | $12.93M derived: sum of 2 quarters · filed 2023-05-11 | $10.91M derived: sum of 3 quarters · filed 2023-05-11 | -$14.69M derived: sum of 4 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | $27.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $25.09M derived: sum of 2 quarters · filed 2022-11-14 | -$503.28K derived: sum of 3 quarters · filed 2022-11-14 | -$35.18M 10-K · filed 2023-03-20 | -$611.07K 10-K · filed 2022-02-17 | |||||
| 2021-09-30 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$27.62M derived: sum of 2 quarters · filed 2022-11-14 | -$27.72M 10-Q · filed 2022-11-14 | -$249.11K 10-Q · filed 2021-11-12 | ||||||
| 2021-06-30 | -$25.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$25.70M 10-Q · filed 2022-08-12 | -$180.16K 10-Q · filed 2021-08-16 | |||||||
| 2021-03-31 | -$107.80K 10-Q · filed 2022-05-16 | |||||||||
| 2020-12-31 | -$316.69K 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |